CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

Clinical trial NCT05105867 · UNKNOWN

Trial details

NCT number: NCT05105867
Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Status: UNKNOWN
Phase: Early Phase 1
Study type: INTERVENTIONAL

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Relapsed or Refractory B-cell Non-hodgkin Lymphoma

Start date: 2021-09-29
Primary completion: 2024-08-31
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.